Researchers reported discovery of a new class of potent antibodies that neutralize both Marburg virus and the related Ravn virus, findings published in npj Viruses. The study characterizes antibody binding profiles and cross‑neutralization breadth, offering concrete candidates for therapeutic development and design inputs for next‑generation vaccines. The antibodies provide defined molecular starting points for preclinical work and potential passive‑immunotherapy strategies against filoviruses.